1.7314
price up icon7.27%   0.0814
 
loading
전일 마감가:
$1.65
열려 있는:
$1.65
하루 거래량:
246.48K
Relative Volume:
0.97
시가총액:
$16.00M
수익:
$486.00K
순이익/손실:
$-28.43M
주가수익비율:
-0.6142
EPS:
-2.8189
순현금흐름:
$-26.75M
1주 성능:
+66.98%
1개월 성능:
+86.32%
6개월 성능:
-47.16%
1년 성능:
-7.81%
1일 변동 폭
Value
$1.641
$1.79
1주일 범위
Value
$1.08
$1.79
52주 변동 폭
Value
$0.85
$4.30

Vyne Therapeutics Inc Stock (VYNE) Company Profile

Name
명칭
Vyne Therapeutics Inc
Name
전화
800-775-7936
Name
주소
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Name
직원
13
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
VYNE's Discussions on Twitter

VYNE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VYNE
Vyne Therapeutics Inc
1.744 16.00M 486.00K -28.43M -26.75M -2.8189
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.73 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
523.87 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.62 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.92 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.00 28.51B 3.81B -644.79M -669.77M -6.24

Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-18 개시 BTIG Research Buy
2021-12-06 재개 H.C. Wainwright Buy

Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스

pulisher
Jun 18, 2025

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Increases By 46.8% - Defense World

Jun 18, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Invests $68,000 in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 09, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Has $80,000 Stock Holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

Jun 04, 2025
pulisher
May 30, 2025

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World

May 30, 2025
pulisher
May 29, 2025

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India

May 29, 2025
pulisher
May 25, 2025

VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World

May 25, 2025
pulisher
May 20, 2025

VYNE Stock Touches 52-Week Low at $1.17 Amid Market Challenges - Investing.com

May 20, 2025
pulisher
May 11, 2025

VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 11, 2025
pulisher
May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025
pulisher
May 09, 2025

VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks

May 08, 2025
pulisher
May 08, 2025

Vyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

VYNE Therapeutics Inc Q1 2025 Earnings: EPS of -$0.20 Beats Estimate, Revenue of $0.2 Million Exceeds Forecast - GuruFocus

May 08, 2025
pulisher
May 08, 2025

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Renaissance Technologies LLC Decreases Stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World

May 08, 2025
pulisher
Apr 28, 2025

VYNE Therapeutics Inc (VYNE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Closing Strong: VYNE Therapeutics Inc (VYNE) Ends at 1.43, Down -23.94 from Last Close - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Market Watch: Renovaro Inc (RENB)’s Noteworthy Gain, Closing at 0.37 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

HC Wainwright Cuts VYNE Therapeutics (NASDAQ:VYNE) Price Target to $4.50 - Defense World

Apr 28, 2025
pulisher
Apr 25, 2025

FDA places clinical hold on VYNE’s psoriasis drug study - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE stock touches 52-week low at $1.38 amid market challenges - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

After A -27.64% Drop In Share Price, Is VYNE Therapeutics Inc (NASDAQ:VYNE) A Better Trade Than Others? - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 25, 2025

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - AOL.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Inc (VYNE) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

FDA places clinical hold on VYNE’s psoriasis drug study By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Provides Update on VYN202 Program | VYNE Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE’s earnings forecast for the current quarter - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down. - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis - Dermatology Times

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics (VYNE) Target Price Cut Following FDA Clinical - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics (VYNE) Faces FDA Clinical Hold on Psoriasis Dr - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

With 36.89% Distance From Low, Could Vs Media Holdings Ltd (NASDAQ:VSME) Post Further Gains? - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 25, 2025

Pre-market Movers: OMEX, SES, VYNE, OLB, LEXX… - RTTNews

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Provides Update on VYN202 Program - The Manila Times

Apr 25, 2025
pulisher
Apr 25, 2025

VYNE Therapeutics Psoriasis Drug Trial Suspended: FDA Flags Critical Safety Issues in Animal Studies - Stock Titan

Apr 25, 2025
pulisher
Apr 24, 2025

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.1% – Here’s What Happened - Defense World

Apr 24, 2025
pulisher
Apr 18, 2025

Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister

Apr 18, 2025
pulisher
Apr 08, 2025

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Yahoo Finance

Apr 08, 2025
pulisher
Apr 04, 2025

Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail

Apr 04, 2025
pulisher
Apr 02, 2025

VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World

Apr 02, 2025
pulisher
Mar 21, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Invesco Canada announces cash distributions for its ETFs - The Globe and Mail

Mar 21, 2025
pulisher
Mar 20, 2025

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan

Mar 20, 2025
pulisher
Mar 11, 2025

Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 11, 2025
pulisher
Mar 08, 2025

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 08, 2025

Vyne Therapeutics Inc (VYNE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.48
price down icon 0.77%
$35.97
price down icon 0.17%
$21.22
price down icon 0.14%
$99.67
price down icon 1.11%
$106.30
price down icon 0.08%
biotechnology ONC
$241.30
price up icon 0.06%
자본화:     |  볼륨(24시간):